This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Gilead, Johnson & Johnson file renewed motion to dismiss BCBS's US antitrust claims over HIV treatment

( June 1, 2022, 22:31 GMT | Official Statement) -- MLex Summary: Gilead and Johnson & Johnson filed a renewed motion to dismiss US antitrust claims filed by Blue Cross Blue Shield accusing them of conspiring to fix prices for combination antiretroviral therapy drugs used to treat human immunodeficiency virus. They argued that newly obtained evidence irrefutably establishes that BCBS has no “skin in the game” because it has never used its “own funds” to pay for pharmacy benefits and does not bear underwriting risk for any benefits for the federal employee program, including pharmacy benefits.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections